clinical trial · NCT06914037
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Peripheral T-cell LymphomaCutaneous T-cell Lymphoma (CTCL)NHL (Non-Hodgkin Lymphoma)CHT101
brief summary
Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
started
Mar 31, 2025
primary completion
Mar 31, 2028
completion
Mar 31, 2028
last updated
Apr 6, 2025
detailed description
3 planned dose cohorts will be evaluated during dose escalation phase. The dose expansion will be initiated after SRC (safety review committee) reviewing available safety, PK and preliminary efficacy data.
official title
A Phase 1, Open-Label, Single-Arm Study of the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol